Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304421 · ClinicalTrials.gov registry record · Phase 4
Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD
A Phase 4 study, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT00304421 is a Phase 4 study that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 23 participants.
The verdict
NCT00304421, a Phase 4 study, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the effect of two different drugs, rabeprazole (20 mg) and pantoprazole (40 mg), and their effects on the amount of acid produced by your stomach on evening and at night after standard protein meal.
Interventions
- DRUG pantoprazole
- DRUG rabeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00304421
The ClinicalTrials.gov registry entry for NCT00304421 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Greater Los Angeles Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pantoprazole is the first listed.
NCT00304421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00304421 about?
NCT00304421 is a clinical study titled "Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD". The purpose of the study is to compare the effect of two different drugs, rabeprazole (20 mg) and pantoprazole (40 mg), and their effects on the amount of acid produced by your stomach on evening and at night after standard protein meal.
What is the current status of trial NCT00304421?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2004-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00304421?
The interventions under investigation include: pantoprazole (DRUG), rabeprazole (DRUG).
Who is sponsoring clinical trial NCT00304421?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.